Subscribe to NRx Newsletter

Our Therapeutic Focus

Acute/Subacute Suicidal Ideation & Behavior (ASIB/SSIB)

More than 100 People End Their Lives Each Day in the United States.60% may be due to Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB)
Bipolar depression in the presence of suicidality is a potentially lethal disease affecting up to three million Americans, as it can sometimes lead to Suicidal Ideation & Behavior (ASIB). This means they require hospitalization as they are at imminent risk of harming themselves. In less severe cases, some individuals with bipolar depression may experience Subacute Suicidal Ideation/Behavior (SSIB). These are people with suicidal thoughts, who do not require hospitalization, yet should be medically monitored.
We’re developing the first oral medicine to treat Bipolar Depression in patients with Acute/Subacute Suidical Ideation & Behavior (ASIB/SSIB).
Learn more about NRX-101 ➡️
Those with Acute Suicidal Ideation/Behavior, as classified by FDA-recognized scales, have a 33% chance of death (need a citation) within six months of onset. Although only 10% of the 30 million Americans suffering with depressive disorders have bipolar disorder, patients with bipolar depression may account for up to 60% of all depression-related suicides.1 Bipolar Depression with ASIB also takes a dramatic economic toll on the U.S. healthcare system. Given the lack of suitable alternatives, the majority of patients are managed at the inpatient setting, which is costly to payers, patients, families, and employers. Pharmacological options are not effective for many patients and typically require more than three weeks to show effect. Other treatments, such as electro-convulsive therapy (ECT), are physically and emotionally draining and require extended hospitalization. Scientific findings  indicate that thoughts and impulses for suicide have biological underpinnings.2 Emerging data suggests (need a citation) that suicidality in bipolar depression may be modulated by the brain’s NMDA receptor, providing a rationale for developing new therapies focused on this target.
  1. Pompili, M. Gonda, X. Bipolar Disorders 2013; 15: 457-490
  2. Johnston et al. American Journal of Psychiatry 2017; 174: 667-675
Our Science

NMDA Receptors

Our Therapeutic Focus

Post-Traumatic Stress Disorder (PTSD)